Literature DB >> 30830695

End-of-Life Care in Patients Exposed to Home-Based Palliative Care vs Hospice Only.

Susan E Wang1, In-Lu Amy Liu2, Janet S Lee2, Peter Khang3, Romina Rosen4, Lynn F Reinke5, Richard A Mularski6, Huong Q Nguyen2.   

Abstract

OBJECTIVES: The current evidence base regarding the effectiveness of home-based palliative care (HomePal) on outcomes of importance to multiple stakeholders remains limited. The purpose of this study was to compare end-of-life care in decedents who received HomePal with two cohorts that either received hospice only (HO) or did not receive HomePal or hospice (No HomePal-HO).
DESIGN: Retrospective cohorts from an ongoing study of care transition from hospital to home. Data were collected from 2011 to 2016.
SETTING: Kaiser Permanente Southern California. PARTICIPANTS: Decedents 65 and older who received HomePal (n = 7177) after a hospitalization and two comparison cohorts (HO only = 25 102; No HomePal-HO = 22 472). MEASUREMENTS: Utilization data were extracted from administrative, clinical, and claims databases, and death data were obtained from state and national indices. Days at home was calculated as days not spent in the hospital or in a skilled nursing facility (SNF).
RESULTS: Patients who received HomePal were enrolled for a median of 43 days and had comparable length of stay on hospice as patients who enrolled only in hospice (median days = 13 vs 12). Deaths at home were comparable between HomePal and HO (59% vs 60%) and were higher compared with No HomePal-HO (16%). For patients who survived at least 6 months after HomePal admission (n = 2289), the mean number of days at home in the last 6 months of life was 163 ± 30 vs 161 ± 30 (HO) vs 149 ± 40 (No HomePal-HO). Similar trends were also noted for the last 30 days of life, 25 ± 8 (HomePal, n = 5516), 24 ± 8 (HO), and 18 ± 11 (No HomePal-HO); HomePal patients had a significantly lower risk of hospitalizations (relative risk [RR] = .58-.87) and SNF stays (RR = .32-.77) compared with both HO and No HomePal-HO patients.
CONCLUSION: Earlier comprehensive palliative care in patients' home in place of or preceding hospice is associated with fewer hospitalizations and SNF stays and more time at home in the final 6 months of life. J Am Geriatr Soc, 2019.
© 2019 The American Geriatrics Society.

Entities:  

Keywords:  end-of-life care; home-based palliative care; hospice

Mesh:

Year:  2019        PMID: 30830695     DOI: 10.1111/jgs.15844

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  5 in total

1.  Characteristics and place of death in home care recipients in Germany - an analysis of nationwide health insurance claims data.

Authors:  Rieke Schnakenberg; Alexander Maximilian Fassmer; Katharina Allers; Falk Hoffmann
Journal:  BMC Palliat Care       Date:  2022-10-06       Impact factor: 3.113

2.  Dementia diagnosis and utilization patterns in a racially diverse population within an integrated health care delivery system.

Authors:  Huong Q Nguyen; Soo Borson; Peter Khang; Annette Langer-Gould; Susan E Wang; Jarrod Carrol; Janet S Lee
Journal:  Alzheimers Dement (N Y)       Date:  2022-03-13

Review 3.  Home Based Palliative Care: Known Benefits and Future Directions.

Authors:  Benjamin Roberts; Mariah Robertson; Ekene I Ojukwu; David Shih Wu
Journal:  Curr Geriatr Rep       Date:  2021-11-25

4.  Factors Related to Family Caregivers' Readiness for the Hospital Discharge of Advanced Cancer Patients.

Authors:  Ru-Yu Huang; Ting-Ting Lee; Yi-Hsien Lin; Chieh-Yu Liu; Hsiu-Chun Wu; Shu-He Huang
Journal:  Int J Environ Res Public Health       Date:  2022-07-01       Impact factor: 4.614

5.  Longitudinal patterns and predictors of healthcare utilization among cancer patients on home-based palliative care in Singapore: a group-based multi-trajectory analysis.

Authors:  Qingyuan Zhuang; Poh-Heng Chong; Whee Sze Ong; Zhi Zheng Yeo; Cherylyn Qun Zhen Foo; Su Yan Yap; Guozhang Lee; Grace Meijuan Yang; Sungwon Yoon
Journal:  BMC Med       Date:  2022-09-22       Impact factor: 11.150

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.